We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

134 hedge funds and large institutions have $136M invested in Xeris Biopharma Holdings in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

361% more call options, than puts

Call options by funds: $932K | Put options by funds: $202K

54% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 35

2% more capital invested

Capital invested by funds: $134M → $136M (+$2.51M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.24% less ownership

Funds ownership: 43.16% → 40.91% (-2.2%)

6% less funds holding

Funds holding: 143 → 134 (-9)

33% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 24

Holders
134
Holders Change
-9
Holders Change %
-6.29%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
54
Reduced
35
Closed
24
Calls
$932K
Puts
$202K
Net Calls
+$730K
Net Calls Change
+$243K

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$1.34M
2
GCP
GSA Capital Partners
United Kingdom
+$1.2M
3
BlackRock
BlackRock
New York
+$749K
4
Renaissance Technologies
Renaissance Technologies
New York
+$690K
5
Morgan Stanley
Morgan Stanley
New York
+$643K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$1.48M
2
SCM
Stonepine Capital Management
Oregon
-$1.32M
3
NMC
NEA Management Company
Maryland
-$926K
4
RCMNY
Rubric Capital Management (New York)
New York
-$687K
5
N
Nuveen
North Carolina
-$500K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$23.2M +$749K +371,572 +4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$17.2M +$102K +50,648 +0.7%
CC
3
Caxton Corporation
New Jersey
$11.5M – – –
MB
4
MPM BioImpact
Massachusetts
$10.9M +$1.34M +664,030 +16%
State Street
5
State Street
Massachusetts
$7.33M +$87.9K +43,617 +1%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$7.29M +$393K +195,015 +6%
RA
7
Rosalind Advisors
Ontario, Canada
$7.02M +$605K +300,000 +11%
Millennium Management
8
Millennium Management
New York
$3.82M +$1.55K +771 +0%
Morgan Stanley
9
Morgan Stanley
New York
$3.62M +$643K +318,966 +25%
CP
10
CenterBook Partners
Connecticut
$3.3M -$157K -77,998 -5%
Renaissance Technologies
11
Renaissance Technologies
New York
$3.04M +$690K +342,300 +34%
N
12
Nuveen
North Carolina
$3.02M -$500K -247,890 -16%
AQR Capital Management
13
AQR Capital Management
Connecticut
$2.68M +$105K +52,074 +5%
Northern Trust
14
Northern Trust
Illinois
$2.49M -$106K -52,386 -5%
RG
15
Redmile Group
California
$2.35M – – –
DMKJ
16
David M. Knott Jr
$1.84M +$443K +220,000 +37%
Bank of America
17
Bank of America
North Carolina
$1.44M +$27.4K +13,619 +2%
Lazard Asset Management
18
Lazard Asset Management
New York
$1.43M +$435K +215,757 +51%
GCP
19
GSA Capital Partners
United Kingdom
$1.36M +$1.2M +593,952 +5,072%
ICM
20
Invenomic Capital Management
Massachusetts
$1.33M -$25.1K -12,434 -2%
Tudor Investment Corp
21
Tudor Investment Corp
Connecticut
$1.29M – – –
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$1.17M -$381K -188,987 -27%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$964K +$161K +80,015 +23%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$950K +$50.7K +25,164 +6%
Charles Schwab
25
Charles Schwab
California
$910K +$77.2K +38,289 +10%
1
2 3 4 5

XERS Hedge Fund Activity: Q2 2024 in Review

134 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2024, worth a combined $136M — up 1.9% from $134M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of XERS and 16 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 54 added.

The largest buyer was MPM BioImpact, adding an estimated $1.34M. The largest seller was Ameriprise, cutting an estimated $1.48M.

  • 134 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2024, down from 143 in Q1 2024.
  • Funds reported $136M of Xeris Biopharma Holdings stock for Q2 2024, up 1.9% quarter-over-quarter.
  • 16 funds opened new Xeris Biopharma Holdings positions in Q2 2024 and 24 closed out, a net change of -8 holders.
  • The largest Xeris Biopharma Holdings buyer in Q2 2024 was MPM BioImpact, an estimated $1.34M added.
  • The largest Xeris Biopharma Holdings seller in Q2 2024 was Ameriprise, an estimated $1.48M sold.

Based on aggregated 13F filings for Q2 2024.